Welcome to our dedicated page for Hillstream BioPharma news (Ticker: hils), a resource for investors and traders seeking the latest updates and insights on Hillstream BioPharma stock.
Hillstream BioPharma, Inc. (NASDAQ: HILS) is a cutting-edge biotechnology company dedicated to developing innovative therapeutic candidates targeting drug-resistant and devastating cancers. The company's proprietary Quatramer™ technology enables targeted delivery and extended action of biologics, mRNA, peptides, and other therapeutic modalities within the tumor microenvironment, minimizing off-target toxicity.
Hillstream's notable advancements include Quatrabody™ conjugates, which exhibit higher binding affinity to immuno-oncology targets than currently approved therapies. Emerging as a leader in immuno-oncology, Hillstream is set to enter the market with its leading candidate HSB-1940, targeting PD-1, followed by other targets such as PD-L1, HER-2, and TROP-2.
Recent achievements highlight Hillstream's exclusive license agreement with the Applied Biomedical Science Institute (ABSI), which allows the company to develop novel antibodies targeting HER2 and HER3. These antibodies are distinct from existing therapies and present a promising approach to treating HER2-positive cancers.
Hillstream's focus on oncology includes developing HSB-3215, a bi-specific antibody targeting HER2 and HER3. Through collaborations with Minotaur Therapeutics and OmniAb, Inc., Hillstream is advancing the development of next-generation biotherapeutics, including Picobodies™ against HER3 and other undisclosed oncology targets.
In addition to oncology, Hillstream is expanding its therapeutic pipeline with the acquisition of AV104, a clinical-stage asset for treating chronic pruritis, including conditions such as primary biliary cholangitis (PBC). This asset utilizes a proprietary transdermal buccal film for effective delivery and high drug concentrations in the skin.
Hillstream BioPharma's strategic focus on advancing its robust immuno-oncology pipeline and acquiring clinical-stage assets positions the company as a significant player in the biotechnology sector. For further information, please visit www.hillstreambio.com.
Hillstream BioPharma, Inc. (Nasdaq: HILS) is set to participate in the Fierce Biotech Summit on September 19-20, 2022, in Boston. The company's CEO, Randy Milby, will engage with key players in the biotech industry to discuss their innovative cancer therapies targeting ferroptosis, a mechanism leading to iron-mediated cell death in resistant cancers. Hillstream aims to expand its pipeline and revenue growth strategies. The summit provides an essential networking platform for executives to enhance partnerships across the drug development spectrum.
Hillstream BioPharma (Nasdaq: HILS) will attend the 12th Annual World Orphan Drug Congress USA 2022 from July 11-13 in Boston. CEO Randy Milby aims to connect with stakeholders in the rare disease sector to advance their cancer therapies targeting ferroptosis. The congress is the largest global event focused on orphan drugs, featuring over 1,700 attendees and 250+ speakers. Hillstream's leading candidate, HSB-1216, has shown promise in treating drug-resistant cancers, and the company plans to start further clinical studies in 2022.
Hillstream BioPharma (HILS) announced a collaboration with Sapien Biosciences to investigate the synergy between its ferroptosis inducer HSB-1216 and immune checkpoint inhibitors (ICIs). The study will explore the potential benefits of combining HSB-1216 with nivolumab and Opdualag®, aiming to enhance cancer immunotherapy efficacy. Previous studies suggest that immunotherapy-activated CD8+ T cells increase ferroptosis-specific lipid peroxidation, making the combination a promising therapeutic strategy. Hillstream intends to start clinical studies later in 2022.
Hillstream BioPharma, Inc. (Nasdaq: HILS) announced a share repurchase program allowing up to $1 million in common stock buybacks, with approximately $11.1 million in cash available as of March 31, 2022. The program aims to capture additional value for investors amidst favorable market conditions. CEO Randy Milby highlighted the company's progress in clinical trials targeting ferroptosis, a promising anti-cancer mechanism. The buyback's timing and execution will depend on market conditions and regulatory guidelines, with no obligation to repurchase a specific number of shares.
Hillstream BioPharma (Nasdaq: HILS) provided a corporate update highlighting significant advancements in its clinical pipeline. The company received FDA Orphan Drug Designation for its lead candidate, HSB-1216, targeting Uveal Melanoma, and for HSB-888, aimed at pediatric osteosarcoma. As of March 31, 2022, Hillstream reported $11 million in cash, sufficient to support operations through 2023. The company presented a roadmap for clinical milestones, including the initiation of Phase 1 trials for HSB-1216 in 2023, indicating a focused strategy on drug-resistant cancers.
Hillstream BioPharma, Inc. (NASDAQ: HILS) announced its participation at BioNJ's 12th Annual BioPartnering Virtual Conference from May 9-13, 2022. The company will present its leading treatment, HSB-1216, which targets solid tumors and has demonstrated a 71% response rate in pilot clinical studies. CEO Randy Milby will be available for a Q&A on May 10, 2022. HSB-1216 holds orphan drug designation for small cell lung cancer and uveal melanoma, highlighting its potential in treating drug-resistant cancers. The conference aims to connect over 500 industry professionals.
Hillstream BioPharma (NASDAQ: HILS) announced promising developments in its clinical programs. The active moiety of HSB-1216 demonstrated a 71% response rate in treating triple-negative breast cancer and epithelial carcinomas during a pilot study. Recently, it received Orphan Drug Designation from the FDA for Uveal Melanoma. Additionally, HSB-888 obtained Rare Pediatric Disease Designation and Orphan Drug Designation for pediatric osteosarcoma. The company continues to progress towards an IND filing and upcoming clinical trials.
Hillstream BioPharma has announced that the US FDA has granted Orphan Drug Designation for HSB-1216, targeting uveal melanoma, a rare and aggressive cancer. This designation highlights the unmet need in treating this condition, where 50% of patients develop metastatic disease. HSB-1216 is a ferroptosis inducer that aims to improve treatment outcomes. The company plans to progress toward an IND filing and initiate clinical trials in solid tumor patients, further diversifying its oncology pipeline.
Hillstream BioPharma (NASDAQ:HILS) announced key updates in its pipeline and a successful $15 million IPO on January 14, 2022. The company is advancing HSB-1216, a novel ferroptosis inducer targeting drug-resistant cancers, with promising results in non-clinical studies. The FDA granted orphan drug designation for HSB-1216 for small cell lung cancer, offering seven years of market exclusivity. Hillstream is also exploring additional indications and leveraging its proprietary Quatramer tumor-targeting platform for enhanced delivery of therapeutics.
Hillstream BioPharma (NASDAQ:HILS) has announced significant upcoming events, including a R&D Day on February 24, 2022, and a Business Review on February 14, 2022. The R&D Day will showcase emerging pipeline assets and anticipated milestones, focusing on innovative therapeutic candidates targeting ferroptosis, an anti-cancer mechanism for treating drug-resistant cancers. The company's lead candidate, HSB-1216, showed positive results in a clinical pilot study in Germany, targeting various solid tumors. The company aims to advance HSB-1216 into further clinical trials this year.
FAQ
What is the market cap of Hillstream BioPharma (hils)?
What does Hillstream BioPharma specialize in?
What is the Quatramer™ technology?
What recent collaborations has Hillstream BioPharma announced?
What is HSB-3215?
What is AV104?
How does Hillstream plan to address unmet needs in oncology?
What other therapeutic areas is Hillstream exploring?
What is the significance of Hillstream's collaboration with ABSI?
What makes Picobodies™ unique?
Where can I find more information about Hillstream BioPharma?
